Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)

详细信息    查看全文

• 作者：Shi-Wen Jiangp>ap>p> ; p>p>bp>p> ; p>p>1p>p> ; p>p>jiang_s@mercer.edup> ; Siliang Xup>bp>p> ; p>p>cp>p> ; p>p>1p> ; Haibin Chenp>dp>p> ; p>p>1p> ; Xiaoqiang Liup>ep>p> ; p>p>fp> ; Zuoqing Tangp>gp> ; Yugui Cuip>cp> ; Jiayin Liup>cp>p> ; p>p>jyliu_nj@126.comp>
• 关键词：SET ; PCOS ; Hyperandrogenism ; Androgen ; Anti-SET ; PP2A
• 刊名：Clinica Chimica Acta
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：464
• 期：Complete
• 页码：155-159
• 全文大小：299 K
• 卷排序：464

文摘

SET is involved in DNA replication, histone modification, nucleosome assembly, and transcriptional control. SET is overexpressed in ovaries of PCOS patients, modulates P450c17, and contributes to hyperandrogenism. SET may bind to human P450c17 promoter and regulate P450c17 expression in human theca cells. SET could be a therapeutic target, and anti-SET drugs such as ceramide could be useful for treating PCOS.